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Brief inhalation of nitric oxide increases
resuscitation success and improves 7-day-
survival after cardiac arrest in rats: a
randomized controlled animal study
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Joachim Weis4, Kay Wilhelm Nolte4, Rolf Rossaint1, Fumito Ichinose5 and Michael Fries6
Abstract
Introduction: Inhaled nitric oxide (iNO) improves outcomes when given post systemic ischemia/reperfusion injury.
iNO given during cardiopulmonary resuscitation (CPR) may therefore improve return of spontaneous circulation
(ROSC) rates and functional outcome after cardiac arrest (CA).
Methods: Thirty male Sprague-Dawley rats were subjected to 10 minutes of CA and at least 3 minutes of CPR.
Animals were randomized to receive either 0 (n = 10, Control), 20 (n = 10, 20 ppm), or 40 (n = 10, 40 ppm) ppm iNO
during CPR until 30 minutes after ROSC. A neurological deficit score was assessed daily for seven days following the
experiment. On day 7, brains, hearts, and blood were sampled for histological and biochemical evaluation.
Results: During CPR, 20 ppm iNO significantly increased diastolic arterial pressure (Control: 57 ± 5.04 mmHg; 20
ppm: 71.57 ± 57.3 mmHg, p < 0.046) and decreased time to ROSC (Control: 842 ± 21 s; 20 ppm: 792 ± 5 s, (p = 0.02)).
Thirty minutes following ROSC, 20 ppm iNO resulted in an increase in mean arterial pressure (Control: 83 ± 4 mmHg;
20 ppm: 98 ± 4 mmHg, p = 0.035), a less pronounced rise in lactate and inflammatory cytokine levels, and attenuated
cardiac damage. Inhalation of NO at 20 ppm improved neurological outcomes in rats 2 to 7 days after CA and CPR.
This translated into increases in 7 day survival (Control: 4; 20 ppm: 10; 40 ppm 6, (p≤ 0.05 20 ppm vs Control and
40 ppm).
Conclusions: Our study revealed that breathing NO during CPR markedly improved resuscitation success, 7-day
neurological outcomes and survival in a rat model of VF-induced cardiac arrest and CPR. These results support the
beneficial effects of NO inhalation after cardiac arrest and CPR.
Introduction
In industrialized countries, sudden cardiac arrest (CA)
remains one of the leading causes of death [1]. Despite
improvements in pre-hospital care and the introduction
of mild therapeutic hypothermia (MTH) [2], mortality
rates of out-of-hospital CA victims are still high, although
regional variations are often reported [3, 4]. Survivors fre-
quently suffer from moderate to severe cognitive deficits 3
months post resuscitation [5, 6]. These poor outcomes are
mainly attributable to a distinct pathology termed post-
CA syndrome [7]. Clinically, this syndrome becomes
apparent as cerebral and myocardial dysfunction [8], often
associated with a pronounced inflammatory response [9]
in concert with microvascular alterations [10, 11] and ad-
renal dysfunction [9, 12].
The benefits of MTH have recently been questioned in
a large study predominantly including patients with ven-
tricular fibrillation and short duration ischemia [13].
Furthermore, in patients with a more severe insult pre-
senting with asystole, MTH is probably even less effective
[14]. Currently no pharmacological agent is available to
further improve outcomes for CA victims.
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Inhaled nitric oxide (iNO) is approved to treat new-
born hypoxemia with pulmonary hypertension [15]. In
addition, iNO has been used in the intensive care setting
as a selective pulmonary vasodilator in patients suffering
from acute respiratory distress syndrome and right heart
failure [16, 17]. Accumulating evidence of preclinical
and clinical studies suggests that iNO also exerts remote
effects independent of its local vasodilatory action. Re-
cently, Minamishima and colleagues demonstrated in a
murine model that breathing 40 ppm NO starting 1 hour
after CA and cardiopulmonary resuscitation (CPR) mark-
edly improved neurological and myocardial function, and
10-day survival rate [18]. Whether or not administration
of iNO during CPR improves resuscitation success rates
was not addressed.
To accelerate the pace of translation of this promising
treatment into the clinic to improve outcomes after CA,
we examined the effects of iNO administered during
CPR until 30 minutes after return of spontaneous circula-
tion (ROSC). We hypothesized that iNO increases resusci-
tation success and improves cerebral and myocardial
outcomes, and survival after prolonged CA in rats.
Methods
The study protocol was approved by the appropriate
ethical Institution (Landesamt für Natur, Umwelt und
Verbraucherschutz Nordrhein-Westfalen; Recklinghausen;
Germany). The experimental procedures were performed
according to the Guide for the Care and Use of Laboratory
Animals formulated by the National Research Council
(National Academies Press, 1996) and the ARRIVE guide-
lines (National Centre for the Replacement, Refinement
and Reduction of animals in research, 2010). In addition,
all reported data and outcomes are in accordance with the
Utstein style guidelines for uniform reporting of labora-
tory CPR research [19].
A total of 30 male Sprague-Dawley rats (Charles River,
Sulzfeld, Germany) weighing between 400–500 g were
investigated in an established rodent CA model [20]. An-
imals were housed in adequately spaced cages (60 cm× 40
cm; type 2000; Tecniplast; Buguggiate; Italy) with a 12-
hour light-dark cycle. Animals had free access to water
and food prior to the study.
Two different concentrations of iNO (20 ppm vs. 40
ppm), administered during CPR until 30 minutes after
ROSC, were tested against 0 ppm iNO (control). Primary
endpoints were resuscitation rates, and neurological out-
come when compared to controls.
Animal preparation
We used a rat model of CA and CPR as previously
described, with minor modifications [20]. On the day
of the procedure, rats were anesthetized with an in-
traperitoneal injection of pentobarbital (45 mg · kg−1).
Additional doses (10 mg · kg−1) of pentobarbital were ad-
ministered if signs of animal discomfort were noted, i.e.,
sudden rise in heart rate (HR), respiratory rate, or tail or
paw movement. The animals’ chests and backs were thor-
oughly shaved to allow for direct contact of the defibrilla-
tor electrodes used for defibrillation during CPR.
After placing the rats on a surgical board in the supine
position, the trachea was orally intubated using a modified
14 G cannula (Abbocath-T, Abbott Hospital Division,
North Chicago, IL, USA). Animals were mechanically ven-
tilated with a specialized ventilator capable of precise de-
livery of NO (Servo Ventilator 300A, Siemens, Munich,
Germany) with an inspired oxygen fraction (FiO2) of 0.3.
Respiratory frequency was adjusted to maintain end-tidal
PCO2 between 35 and 40 mmHg, continuously monitored
using an infrared CO2 analyzer (Cap Star 100, CWE Inc.,
Ardmore, PA, USA). A three-lead electrocardiogram was
continuously measured using monopolar needle elec-
trodes (MLA1204 Needle Electrodes, AD Instuments,
Oxford, UK). The left femoral artery was surgically ex-
posed, cannulated with a polyethylene catheter (PE 50)
and connected to a high sensitivity transducer (Capto SP
844 Physiologic Pressure Transducer, Capto Inc., Skop-
pum, Norway) for the measurement of mean and diastolic
arterial pressure (MAP and DAP). The left femoral vein
was cannulated with an additional PE 50 catheter to allow
for administration of fluids and epinephrine during
CPR. Rectal temperature was monitored and main-
tained between 37.0 and 37.5 °C with the aid of a heating
mat (TCAT-2LV-controller, Physitemp Science Products,
Hofheim, Germany). All catheters were flushed inter-
mittently with saline solution containing 2.5 IU · ml−1 of
heparin.
Experimental procedure
After preparation, animals were randomly assigned to
three groups using the sealed envelope method. Animals
received either 20 ppm (n = 10) or 40 ppm (n = 10) iNO,
started with initiation of ventilation during CPR or no
iNO treatment (control, n = 10).
Ventricular fibrillation (VF) was induced by transesoph-
ageal electrical stimulation. After placing the electrode
using fluoroscopy guidance, alternating current (10 V, 50
Hz) was delivered to the heart using a commercially avail-
able fibrillator (Fi 20 M, Stockert GmbH, Freiburg,
Germany). CA was confirmed by an abrupt decrease in
MAP to less than 20 mmHg. Simultaneously, ventilation
was stopped. After 10 minutes of untreated CA, CPR was
initiated including mechanical ventilation with an FiO2 of
1.0 at a respiratory rate of 50 · min−1, and chest compres-
sions delivered by a custom made mechanical thumper at
a stroke rate of 200 · min−1. Animals in the iNO-treated
groups were additionally given either 20 ppm or 40 ppm
NO until 30 minutes after ROSC. All animals received an
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intravenous bolus of 0.02 mg · kg−1 epinephrine adminis-
tered via the femoral access 30 seconds after starting chest
compressions, which was repeated when MAP fell
below 50 mmHg. After 3 minutes of CPR, external defib-
rillation with 5 J (Zoll MSeries, Zoll Medical Corporation,
Chelmsford, MA, USA) was attempted up to three times.
If ROSC was not achieved, administration of epinephrine
at the same dosage and chest compressions were repeated
for 1 minute before additional direct current counter
shocks (again up to three times) were delivered. This cycle
was repeated up to three times. ROSC was confirmed by
spontaneous cardiac rhythm in conjunction with a rise in
MAP to greater than 50 mmHg. If no ROSC was achieved
within 3 minutes after the first shock, resuscitation at-
tempts were stopped. Thirty minutes after successful
resuscitation, FiO2 was reduced to 0.3 in all groups, and
iNO administration was stopped. Animals were weaned
from the ventilator and returned to their cages.
Measurements
Ischemia time was calculated as the sum of the duration
of VF (10 minutes), CPR (3 minutes) and the additional
time needed to achieve ROSC (at most 3 additional mi-
nutes of CPR). Heart rate, MAP, DAP and end-tidal CO2
were continuously recorded on a multichannel recorder
(Power Lab, AD Instruments, Spechbach, Germany). Ar-
terial blood samples were drawn at baseline, 30 minutes,
and 1 hour after ROSC. Partial pressure of arterial oxy-
gen (PaO2) and of carbon dioxide (PaCO2), glucose,
lactate levels and base excess were measured using a
conventional blood gas analyzer (ABL700, Radiometer,
Copenhagen, Denmark).
At the same time points and on day 7 post arrest, add-
itional blood samples (0.5 mL) were drawn and centrifuged
for 10 minutes at 2500 ×G and 4 °C. The supernatant
serum was immediately stored at −80 °C for subse-
quent analysis of tumor necrosis factor-alpha (TNF-
α), interleukin (IL)-1ß and IL-6 using a magnetic
bead-based multiplex assay (PCYTMAG-3 K, Merck-
Millipore, Darmstadt, Germany) and a flow cytometry-
based analyzer (LUMINEX® 100/200TM system, Austin,
TX, USA). Migration inhibitory factor (MIF) levels in the
serum samples were assessed using a modified mouse/hu-
man combination ELISA technique as described previ-
ously [21].
Neurological testing
Neurological deficit score
On the 7 days following CPR, neurological performance
was evaluated daily by investigators blinded to the ani-
mal’s treatment using a neurological deficit score (NDS)
previously established in an asphyxial CA model [22]
and validated by our group [23]. The test consists of
six items rep, and coordination. Each item is graded
depending on the severity and given a score. The
score ranges from 0 (worst neurological impairment) to
500 (no neurological impairment). Deceased animals did
not receive a score and were excluded from further
analysis.
Histopathology
Seven days after successful resuscitation, rats were re-
anesthetized as described above. A midline thoracotomy
was performed and the animals were transcardially per-
fused with 100 mL of NaCl 0.9 %.
Neurohistopathology
After transcardiac perfusion, brains were carefully re-
moved and trans sagitally cut in half. Right hemispheres
were post fixed in buffered 4 % paraformaldehyde. Stan-
dardized coronal slices were taken at a thickness of 2 mm
resulting in a total of 8 slices per brain. The neocortex, hip-
pocampal CA1 and anterior and posterior CA 3/4 sectors,
and basal ganglia were chosen as regions of interest, and
analyzed by an experienced neuropathologist blinded to
the animal’s treatment assignment. Conventional hema-
toxylin/eosin (HE) and NeuN (Mouse anti-Neuronal
Nuclei, monoclonal, Cat # MAB 377, Millipore, Darmstadt,
Germany) staining was performed. A neuronal damage
index was semiquantitatively assessed as previously estab-
lished in this model [20, 23]. The proportion of neuronal
cells with shrunken and/or hypereosinophilic cytoplasm
(HE staining) in combination with a loss of NeuN-
immunoreactivity was determined and summarized in a
score: 0–5 % = 1; 5–10 % = 2; 10–20 % = 3; 20–30 % = 4;
30–40 % = 5; 40–50 % = 6; 50–60 % = 7; 60–70 % = 8; 70–
80 % = 9; 80–90 % = 10; and 90–100 % = 11. Additionally
activation of caspase 3 was assessed by immunohistochem-
istry using a rabbit monoclonal antibody against cleaved
caspase 3 (Rabbit anti-cleaved Caspase-3 (Asp175), mono-
clonal, Cat # 9664, Cell Signaling Technology, Danvers,
MA, USA) according to the protocol recommended by the
manufacturer. Brain slices from an animal 6 hours after in-
duction of subarachnoid hemorrhage served as positive
control for the staining [24]. Animals not surviving until
day 7 were excluded from histopathological analysis.
Myocardial histopathology
After transcardial perfusion, the hearts were gently
removed and transversally bisected. Both atria and rem-
nants of the aortic arch were removed, before fixation in
4 % buffered formalin for at least 24 hours. After paraf-
fin embedding, standardized cross-sections of the ven-
tricular parts were taken at a thickness of 2 μm resulting
in a total of 10 slices per heart. Luxol fast blue (LFB)
staining and counterstaining with nuclear fast red was per-
formed according to a standard protocol [25]. Planimetric
analysis was performed by two blinded investigators, and
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validated by an experienced pathologist, using ImageJ
software (version 1.46r, National Institutes of Health,
Bethesda, MD, USA). LFB positive controls (infarcted
rat hearts) were used to calibrate the software to a thresh-
old value for the detection of blue color (blue transverse
banding and diffuse blue myocytes) to distinguish myo-
fibrillar degeneration (LFB, blue), and normal tissue (nu-
clear fast red, purple). The values for the planimetric
analysis of the two experimenters were averaged and tis-
sue damage was expressed as percentage of blue staining
from the total area.
Statistical analysis
All data are expressed as mean ± standard error of the
mean (SEM). Continuous data were analyzed using un-
paired two-way repeated measures analysis of variance
(ANOVA) with the Tukey post hoc test. Parameters at
distinct time points were tested for significant differ-
ences between the groups by two-way ANOVA with the
Tukey correction. Differences in survival rates were ana-
lyzed by the log-rank test followed by post hoc analysis
with the log rank Bonferroni correction. Statistical ana-
lyses were performed using IBM SPSS statistic 20 and
GraphPad Prism 6.04 (GraphPad Software Inc.) with a
two-tailed hypothesis. In all cases, a p value ≤0.05 was
considered to indicate statistical significance. On the
basis of data derived from pilot experiments, power and
sample size calculations were performed using PS: Power
and Sample Size Calculation version 2.1.31 software by
Dupont and Plummer [26].
Results
Application of 20 ppm iNO significantly increased DAP
during CPR (Fig. 1) and significantly decreased time to
ROSC in comparison to untreated controls (20 ppm:
792 ± 5 s vs. 40 ppm: 798 ± 9 s vs. control: 842 ± 21 s;
p = 0.02 20 ppm vs. control). This translated into pro-
nounced increases in ROSC rates (control: n = 7, 20
ppm: n = 10, 40 ppm n = 6) and significant differences
in the 7-day survival in comparison to animals receiving
no iNO treatment (Fig. 2).
There were no significant differences in the number of
doses of epinephrine during CPR between groups of
animals achieving ROSC (20 ppm: 1.14 ± 0.3 vs. 40 ppm:
1.75 ± 0.3 vs. control: 2.29 ± 0.5).
No significant differences were observed in hemody-
namics, variables of gas exchange, or glucose and lactate
concentrations, between iNO-treated animals and the
control group at baseline (Table 1, Fig. 3). In control ani-
mals, we observed a transient decrease in MAP with a
dramatic increase in lactate and glucose levels following
ROSC. While both iNO-treated groups presented with
higher MAP, lower lactate levels and concurrently higher
base excess post ROSC, we only observed a statistically
significant difference for these parameters in 20-ppm-
treated animals versus controls (Fig. 3). Furthermore,
inhalation of NO attenuated the frequently observed
increase in glucose levels after ROSC, however this was
not statistically significant.
Successfully resuscitated animals exhibited an increased
release of MIF and TNF-α, which was reduced by inhal-
ation of NO (Fig. 4). IL-1ß and IL-6 levels were below de-
tection levels of the magnetic bead-based multiplex assay
(IL1-ß 2,4 - 10.000 pg/mL; IL-6 73,2 - 30.000 pg/mL) at
the given time points.
We observed severe neurological dysfunction as mea-
sured with the NDS in all control animals during the 7
days after CA and CPR. In contrast, 20 ppm iNO mark-
edly improved neurological function 2–7 days after CA
and CPR (Table 2).
Neurohistopathological evaluation revealed that 40
ppm iNO attenuated the neocortical injury in surviving
rats 7 days after CA and CPR (Table 3, Fig. 5a-d). There
was no difference between treatment groups in the
extent of histological brain injury in other regions of
the brain. We did not observe caspase-3 activation in
brain sections from any of the groups 7 days after CA
(Fig. 6).
We observed that CA and CPR caused myocardial
damage in control rats as demonstrated by LFB staining
Fig. 1 Diastolic arterial pressures (DAP) during cardiopulmonary
resuscitation (CPR). Application of 20 ppm inhaled nitric oxide (iNO)
during CPR significantly increased DAP in comparison to untreated
controls; †p <0.05 for 20 ppm iNO vs. control; mean ± standard error
of the mean. Data based on 10 animals in each group
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which was significantly attenuated by inhalation of 20
ppm NO (Fig. 7a and b).
Discussion
Our study demonstrates that ventilation with 20 ppm
iNO, but not 40 ppm iNO during resuscitation until 30
minutes after ROSC, increases DAP during CPR, result-
ing in a decreased time to ROSC. The beneficial effects
of iNO were associated with higher MAPs, lower lactate
levels, and a reduced inflammatory response post ROSC
in comparison to control animals. Furthermore, CA-
induced cardiac damage was markedly attenuated in ani-
mals treated with 20 ppm iNO and brain neocortical
injury was ameliorated by 40 ppm iNO. Last, breathing
20 ppm NO improved neurological outcomes and 7-day
survival rates in rats.
Our study corroborates previous findings of beneficial
effects of iNO on neurological damage and mortality
when given after CA in mice [27]. Minamishima and
colleagues exposed spontaneously breathing mice for 23
hours to 40 ppm NO starting 1 hour after CPR. They
observed marked increases in brain water diffusion in
the hippocampus, caudoputamen and cortex, indicative
of tissue edema in control animals after CA and CPR.
Breathing NO markedly ameliorated brain injury and
improved neurological function and 10-day survival rate
in mice [18]. The same group recently reported that
combining iNO with MTH improved outcomes after CA
in mice compared to MTH alone [27]. The current study
sought to explore the immediate and delayed effects of
iNO given during and after CA. While administration of
iNO during CPR may currently be difficult to realize in
a clinical setting, in the near future a recently developed
novel NO-delivery device may enable administration of
iNO in the field, without the need for cumbersome gas
tanks [28].
Several other investigations report beneficial effects of
iNO on neurological outcomes in parallel with histo-
pathologic alterations in models of stroke or traumatic
brain injury [29–31]. Our study confirms these protect-
ive effects of iNO on outcome in the setting of VF-
induced CA and CPR in rats, a model that is arguably
more clinically relevant than KCL-induced arrest in
mice. In our study, the beneficial effects of iNO on the
neurological outcome was only partially reflected in the
histopathological findings; neocortical injury was amelio-
rated by iNO at 40 ppm, but not at 20 ppm. This might
be due to the fact that several animals in both the iNO
and the control group died during the 7-day observation
period, and were therefore unavailable for further histo-
pathologic examination (Fig. 2). It is likely that we did
not observe cleaved caspase-3 in the brain sections 7
days after CA because caspase-3 is activated at earlier
time points after ischemic insult [18] (Fig. 6).
The beneficial effects of NO on the brain are likely
mediated by several mechanisms. In animal models of
stroke in mice and sheep, iNO administration led to sig-
nificant improvements in both regional cerebral blood
flow [31] and microvascular blood flow [29] in the pen-
umbra via cyclic guanosine monophosphate-dependent
cerebral vasorelaxation. Alternatively, iNO may attenu-
ate inflammatory response [32]. Recent studies suggested
salutary effects of iNO on markers of inflammation and
oxidative stress in patients undergoing cardiac surgery
[33]. In line with this, our study reveals that 20 ppm
iNO significantly attenuates the release of TNF-α and
MIF in rats after CA and CPR. MIF is an upstream regu-
lator of the initial immune response with various pro-
Fig. 2 Seven-day survival in all groups. Animals treated with 20 ppm inhaled nitric oxide (iNO) had significantly better 7 day survival in comparison to
control animals; †p <0.05 for 20 ppm iNO vs. control. CPR cardiopulmonary resuscitation
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inflammatory effects [34], which initiates and exacer-
bates chronic and acute inflammatory disorders [35].
MIF regulates the production and release of TNF-α, IL-
1β, IL-2, IL-6, IL-8, IL-12 and interferon (IFN)-γ [34,
35]. Furthermore MIF has unique characteristics in its
rapid release profile in response to pathogenic stimuli
(e.g., hypoxia, infection, or inflammation) from several
cell types including T cells, macrophages, endothelial
cells, thrombocytes and cardiomyocytes, which is due to
its storage in preformed intracellular pools [34, 35]. In
the heart, MIF is released by ischemic cardiomyocytes
and acts by autocrine/paracrine signaling. Inhibition of
MIF pro-inflammatory activities after ischemia has been
shown to improve cardiomyocyte survival and myocardial
function [36, 37]. Therefore, it is suggested that ele-
vated post-ischemic MIF levels exacerbate ischemic
tissue damage after myocardial ischemia and reperfu-
sion. [38] Along these lines, our observations suggest
that iNO may exert cardioprotective effects after CA
Table 1 Physiologic data
BL PR 30 PR 60
HR (bpm) Control 378 ± 11 336 ± 9 364 ± 20
20 pm iNO 360 ± 15 344 ± 12 372 ± 15
40 ppm iNO 389 ± 9 383 ± 11 402 ± 12
Hgb (g/dL) Control 14.5 ± 0.2 15.8 ± 0.4 16.2 ± 0.5
20 pm iNO 14.6 ± 0.3 15.9 ± 0.2 15.5 ± 0.4
40 ppm iNO 14.2 ± 0.3 15.3 ± 0.5 15.2 ± 0.4
CO-Hba (%) Control 0.4 ± 0.1 0.1 ± 0.1 0.4 ± 0.1
20 pm iNO 0.5 ± 0.1 0.8 ± 0.3 0.0 ± 1.1
40 ppm iNO 0.5 ± 0.1 0.1 ± 0.5 0.4 ± 0.3
Glucose (mg/dL) Control 139 ± 5 306 ± 28 190 ± 29
20 pm iNO 129 ± 5 240 ± 14 179 ± 15
40 ppm iNO 125 ± 7 204 ± 16 141 ± 13
HCO3ˉ Control 27.4 ± 0.3 14.8 ± 1.7 22.2 ± 0.1
20 pm iNO 27.1 ± 0.4 19.2 ± 1.0 23.0 ± 0.4
40 ppm iNO 26.7 ± 0.6 18.7 ± 0.6 22.7 ± 0.1
Ph Control 7.4 ± 0.0 7.2 ± 0.1 7.4 ± 0.0
20 pm iNO 7.4 ± 0.1 7.3 ± 0.0 7.4 ± 0.0
40 ppm iNO 7.4 ± 0.1 7.3 ± 0.0 7.4 ± 0.0
PaO2 (mmHg) Control 131 ± 8 301 ± 36 121 ± 5
20 pm iNO 136 ± 9 253 ± 38 122 ± 11
40 ppm iNO 124 ± 6 271 ± 21 132 ± 10
PaCO2 (mmHg) Control 42 ± 2 42 ± 3 41 ± 3
20 pm iNO 42 ± 2 48 ± 3 40 ± 2
40 ppm iNO 41 ± 1 40 ± 2 38 ± 1
Temperature (°C) Control 37.4 ± 0.1 37.2 ± 0.2 37.4 ± 0.1
20 pm iNO 37.3 ± 0.1 37.4 ± 0.1 37.4 ± 0.1
40 ppm iNO 37.4 ± 0.0 37.3 ± 0.1 37.3 ± 0.1
Physiologic data for control and iNO-treated animals at baseline and after
cardiopulmonary resuscitation. Temperature indicates body temperature estimated
using a rectal probe. *P <0.05 vs. control; mean ± standard error of the mean. Data
based on 10 animals in each group on BL. PR30 and PR60: control, n = 7; 20 ppm,
n = 10; 40 ppm, n = 6. BL baseline, PR time post resuscitation in minutes, HR heart
rate, Hgb hemoglobin, CO-Hba carboxyhemoglobin in arterial blood, PaO2 arterial
oxygen tension, PaCO2 arterial carbon dioxide tension
Fig. 3 Alterations in mean atrial pressure (MAP), lactate levels and base
excess before cardiac arrest and after return of spontaneous circulation
(ROSC). The decrease in MAP and concurrent increase in lactate was
significantly less pronounced in animals treated with 20 ppm inhaled
nitric oxide (iNO) in comparison to controls. Inhalation of NO
attenuated the decrease in base excess, being significant in animals
that received 20 ppm iNO in comparison to controls. †P <0.05 for 20
ppm iNO vs. control; mean ± standard error of the mean. Data based
on 10 animals in each group at baseline (BL). All other time points:
20 ppm, n = 10; 40 ppm, n = 6; Control, n = 7. PR post return of ROSC
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and CPR by inhibiting MIF activity. Additionally, iNO
may preserve the blood-brain barrier by preventing apop-
tosis of cerebral tissue, a mechanism that has been previ-
ously described as a driver of cognitive dysfunction after
subarachnoid hemorrhage [39].
The protective effects of iNO in our study may also be
explained by improved hemodynamics during and after
resuscitation. We noted that iNO significantly improved
DAP during CPR and this might be a result of increased
left ventricular filling. iNO is known to lower pulmonary
artery pressure, hence enhancing transpulmonary blood
flow. Indeed, dramatic increases in pulmonary artery
pressure with concurrent reductions in pulmonary blood
flow are well-documented during closed chest compres-
sions in humans and animals [40–42]. Therefore it is
conceivable that iNO-induced pulmonary vasodilation
improved hemodynamics in our study by enhancing left
ventricular filling leading to the improved ROSC rates.
In fact, in a recent study in a large animal model of CA
and CPR, we observed that iNO markedly decreased
pulmonary vascular resistance and increased coronary
perfusion pressure [43]. Furthermore, the pulmonary
vasodilating effects of iNO might also account for im-
proved hemodynamics and metabolic alterations until 30
minutes post arrest, as we observed significantly higher
MAPs, while the arterial lactate level was reduced by
almost 100 %. Here again, reductions in right ventricular
afterload might explain these findings, as right ventricu-
lar dysfunction is common in survivors of CA [44].
Inhaled nitric oxide may improve cardiac function via
extrapulmonary effects. For instance, iNO has been shown
to improve cardiac function not only through unloading
the right ventricle (RV) and thus improving left ventricu-
lar (LV) preload, but also through direct effects on con-
tractility [45]. Consistent with a previous study by
Dezfulian and colleagues, our results showed that iNO
markedly attenuated myocardial injury as demonstrated
by LFB staining. By its ability to act as an anti-oxidant,
iNO may also prevent injury to vascular smooth muscle
cells caused by reactive oxygen species [46], and may
therefore preserve an adequate vascular tone. Tissue per-
fusion may furthermore be improved by the ability of iNO
to inhibit platelet aggregation [47].
We propose a dual mechanism of action for iNO in
the setting of CA and CPR, which first allows for im-
proved resuscitation success by increased left ventricular
filling and then exerting secondary actions on cerebral
microvasculature and the inflammatory response. While
both effects appear to contribute to the pro-survival
Fig. 4 Release of cytokines, migration inhibitory factor (MIF) and
TNF-α. Successfully resuscitated animals had rising values of circulating
TNF-α and MIF, which was significantly diminished by inhalation of
20 ppm nitric oxide (NO). †P <0.05 for 20 ppm inhaled nitric oxide
(iNO) vs. control; mean ± standard error of the mean. Data based on
10 animals in each group at baseline (BL). Thirty minutes (PR30) and
60 minutes (PR60) post return of spontaneous circulation: 20 ppm,
n = 10; 40 ppm, n = 6; Control, n = 7. Day 7: 20 ppm, n = 10; 40 ppm,
n = 6; Control, n = 4
Table 2 Neurologic deficit score
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Control 300 ± 99 308 ± 104 373 ± 85 390 ± 94 390 ± 94 390 ± 94 403 ± 82
20 pm iNO 393 ± 157 473* ± 43 479* ± 37 482* ± 23 485* ± 24 487* ± 18 488* ± 17
40 ppm iNO 376 ± 85 398 ± 70 430 ± 54 454 ± 40 471 ± 36 463 ± 43 467 ± 45
Neurological deficit score on all days following cardiac arrest and cardiopulmonary resuscitation. Control animals exhibited severe neurological dysfunction.
Inhaled nitric oxide (iNO)-treated animals had better neurological outcomes, with a statistically significant difference in animals treated with 20 ppm iNO on
postoperative days 2–7; *p <0.05 for 20 ppm iNO vs. control; mean ± SD. Day 1: Control, n = 5; 20 ppm iNO, n = 10; 40 ppm iNO, n = 6. Days 2–7: Control, n = 4;
20 ppm iNO, n = 10; 40 ppm iNO, n = 6
Brücken et al. Critical Care  (2015) 19:408 Page 7 of 13
effects of iNO, the hemodynamic effects appear to be
more crucial in this particular setting, as optimal hemo-
dynamics during CPR are the prerequisite for ROSC. Add-
itionally, altered tissue perfusion can modify reactions on
cellular and sub-cellular levels as a secondary effect. How
iNO exerts extrapulmonary effects remains incompletely
understood. It has been suggested that NO is transported
to remote organs as more stable bioactive molecules in-
cluding iron nitrosyl [48], S-nitrosothiols [49], nitrite [50],
and nitrosolipids [51]. Previous studies showed that bene-
ficial effects of iNO after CA and CPR were associated
with marked increase in serum nitrite levels [18, 27]. Al-
though the exact mechanisms of endocrine effects of NO
remain elusive, the current study supports the hypothesis
that iNO exerts extra-pulmonary effects in remote organs
after CA and CPR.
In the current study, the most prominent pro-survival
effects were observed with 20 ppm iNO, while histo-
logical neocortical injury was ameliorated by 40 ppm
iNO. This is in contrast to previously published data
from Kida and colleagues who found optimal survival
rates after CA in mice using 40 and 60 ppm iNO con-
comitantly with MTH [27]. These differences might be
Fig. 5 Representative photomicrograph of HE and NeuN staining of the neocortex (a), hippocampal CA1 (b) and anterior and posterior CA 3/4 sectors
(c), and basal ganglia (d) showing numerous damaged neurons (black arrows) in a control animal and less necrosis in an animal treated with 20 ppm
inhaled nitric oxide (iNO). Scale bars 90 μm (a), 180 μm (b), 180 μm (c), 90 μm (d). Cerebral tissue harvested 7 days post cardiac arrest
Table 3 Neuronal damage index
NDI Neocortex CA 1 CA 3/4 Basal ganglia
Control 2.25 ± 0.25 2.00 ± 0.71 2.50 ± 1.10 1.00 ± 0.00
20 pm iNO 2.00 ± 0.15 2.50 ± 0.50 1.60 ± 0.31 1.10 ± 0.10
40 ppm iNO 1.60* ± 0.25 3.20 ± 1.20 1.60 ± 0.40 1.00 ± 0.00
Conventional hematoxylin/eosin and NeuN (Mouse anti-Neuronal Nuclei) staining
was performed. A neuronal damage index (NDI) was semiquantitatively assessed
in neocortex, hippocampal CA1 and CA 3/4 sectors. *P <0.05 for 40 ppm inhaled
nitric oxide (iNO) vs. control mean ± standard error of the mean. Data based on
cerebral tissue taken from Control animals (n = 4), and animals treated with 20
ppm (n = 10), and 40 ppm (n = 5) iNO
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explained by the different timing of NO inhalation, use
of MTH in the Kida study, or limited sample size in both
studies. In general, positive effects were observed across
a wide range of iNO concentrations (5–50 ppm) in all of
the abovementioned investigations [18, 27, 29–31, 52, 53].
The reason why 40 ppm iNO did not improve survival in
the current study is unknown at this point. However, it is
important to note that iNO at 40 ppm did not worsen
survival after CA compared to the air-breathing con-
trols, suggesting that iNO at 40 ppm is not exerting
any toxic effects. While breathing very high con-
centrations of NO (≥80 ppm) at the time of reperfu-
sion may exert toxic effects, presumably by increasing
peroxinitrite [31], it has never been observed at 40
ppm iNO in a large number of preclinical and clinical
studies [54].
Fig. 6 Representative photomicrograph of immunohistochemical staining for cleaved caspase 3 of the neocortex (a), hippocampal CA1 (b) and
anterior and posterior CA 3/4 sectors (c), and basal ganglia (d). No caspase activation was found in any of the groups. Scale bar 90 μm. e Gyrus
dentatus of an animal 6 hours after induction of subarachnoid hemorrhage as positive control for the staining. Scale bar 30 μm. Cerebral tissue
harvested 7 days post cardiac arrest. iNO inhaled nitric oxide
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We recognize several limitations in the interpretation
of our findings. First, data were obtained from healthy
animals, and translation of results to humans with pre-
existing diseases has always to be performed with caution.
Second, it might well have been that iNO also influenced
plasma cytokine levels of IL-1ß and IL6, which we did not
detect in our short time frame until 1 hour post CA.
Third, post-resuscitation care was not provided in our
protocol, possibly resulting in premature death of animals
in the control and 40-ppm iNO groups. Having additional
survivors on day 7 might have very well influenced
the results. However, early neurologic failure is the
most common mode of death in humans [55]. As CA
was electrically induced in this model, deaths in the
early post-resuscitation phases may be the result of
cardiovascular collapse rather than pure neurocognitive
dysfunction [56]. However, as deceased animals were ex-
cluded from further neurocognitive evaluation, this uncer-
tainty did not affect the results of the NDS-based
neurocognitive evaluation. As stated above, our study can-
not discern whether the effects on hemodynamic function
and neurologic outcomes are solely attributable to direct
effects of iNO at a cellular level or whether improved
myocardial performance resulted in better organ perfu-
sion, which in turn resulted in improved functional recov-
ery. We believe both alterations act in concert to achieve
the benefits of iNO during CPR seen in this investigation.
Although central venous pressure measurements may
Fig. 7 Successful cardiopulmonary resuscitation resulted in cardiac myofibrillar degeneration detected by luxol fast blue staining (LFB). Cardiac
tissue harvested 7 days post cardiac arrest. a Cardiac damage was significantly less pronounced in animals treated with 20 ppm inhaled nitric
oxide (iNO) in comparison with untreated controls. Box: bottom and top represent the first and third quartiles, band represents the median,
whiskers mark the minimum and maximum of the data. †P <0.05 for 20 ppm iNO vs control. Control, n = 4; 20 ppm, n = 10; 40 ppm, n = 6.
b Representative photomicrographs of heart cross-sections with LFB and hematoxylin/eosin (HE) counterstaining of a control, and from a
20-ppm, or 40-ppm iNO-treated animal. The planimetry analysis with imageJ software discriminates between myofibrillar degeneration
(LFB blue staining, yellow markers) and undamaged tissue (HE counterstaining, purple)
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provide further information, we chose to minimize trauma
to optimize our model for the examination of the effects
of iNO on long-term neurological outcomes.
Conclusions
We conclude that 20 ppm iNO administered at the on-
set of CPR and continued for 30 minutes after successful
resuscitation led to increased CPR success and improved
7-day survival in rats. In addition, the inflammatory
response and cardiac damage were attenuated, and
neurological performance was significantly improved by
NO inhalation. Although 40 ppm iNO attenuated histo-
logical neocortical injury after CA, it did not improve
survival rates and neurological function compared to air.
It is important to note that 20 ppm is the standard starting
concentration of iNO in vast majority of clinical settings.
Thus, our findings that breathing NO at 20 ppm for a
short period of time during CPR markedly improves long-
term outcomes after CA is highly clinically relevant. These
findings should encourage clinical evaluation of iNO,
given the well-known and established safety profile of NO
inhalation in adult and pediatric patients. Additional
large-animal studies are also warranted to elucidate the
mechanisms responsible for the beneficial effects of in-
haled NO.
Key messages
 20 ppm of iNO increases CPR success and survival
 20 ppm of iNO improves clinical outcomes after
CPR in rats
 Given the well-known and established safety profile
of NO inhalation in adult and pediatric patients,
these findings should encourage clinical evaluation
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